Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC)

Fig. 4

Immunohistochemical staining and ALK-Fluorescence In Situ Hybridization Evaluation (FISH) scanning images of patient-derived lung cancer tumor tissues and lung cancer PDOs. (A - F) IHC analysis of tumor tissue and PDO from ALK-positive patients (LC_01T, 02T, 03PE, 04T, 08PE and 09PE) verified similar ALK-positive expression patterns, respectively. Fluorescence In Situ Hybridization Evaluation (FISH) evaluation of ALK-EML4 break apart/split signal is the gold standard to investigate ALK rearrangement status. Scanned images showing fused red/green signals representing normal copies of the ALK (yellow arrows) and single red and green signals (red and green arrows) indicating that chromosomal break occurred between the 3 and the 5 contigs. ALK-EML4 break apart was verified in patient tissue (analysis was not performed in LC_04T patient), and ALK-EML4 break apart was also verified in PDO derived from ALK-positive patients (analysis was not performed in LC_01T, 08PE and 09PE)

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us